Search results
Results from the WOW.Com Content Network
[54] [55] The $875 million settlement broke down to $290 million for violating the Prescription Drug Marketing Act, $559.5 million to settle federal fraud charges for overcharging Medicare, and $25.5 million reimbursement to 50 states and Washington, D.C., for filing false claims with the states' Medicaid programs. [55]
A gonadotropin-releasing hormone agonist (GnRH agonist) is a type of medication which affects gonadotropins and sex hormones. [1] They are used for a variety of indications including in fertility medicine and to lower sex hormone levels in the treatment of hormone-sensitive cancers such as prostate cancer and breast cancer, certain gynecological disorders like heavy periods and endometriosis ...
[3] [4] It is a decapeptide (pGlu-His-Trp-Ser-Tyr- D -Trp-Leu-Arg-Pro-Gly-NH 2 ) and a gonadotropin-releasing hormone agonist (GnRH agonist) used as the acetate or pamoate salts . Primary indications include endometriosis , [ 5 ] for the reduction of uterine fibroids , to treat prostate cancer , and to treat male hypersexuality with severe ...
[citation needed] It is administered as either multiple 0.25 mg daily subcutaneous injections or as a single-dose 3 mg subcutaneous injection. The duration of the 3 mg single dose is four days; if human chorionic gonadotropin (hCG) is not administered within four days, a daily 0.25 mg dose is started and continued until hCG is administered.
Mirabegron is the first clinically available beta-3 agonist with approval for use in adults with overactive bladder. Mirabegron was approved for medical use in the United States and in the European Union in 2012. [8] [9] [3] In 2022, it was the 222nd most commonly prescribed medication in the United States, with more than 1 million prescriptions.
Bicalutamide, sold under the brand name Casodex among others, is an antiandrogen medication that is primarily used to treat prostate cancer. [10] It is typically used together with a gonadotropin-releasing hormone (GnRH) analogue or surgical removal of the testicles to treat metastatic prostate cancer (mPC).
Two intermittent 3-months treatment courses of ulipristal acetate 10 mg resulted in amenorrhea at the end of the first treatment course in 79.5%, at the end of the second course in 88.5% of subjects. Mean myoma volume reduction observed during the first treatment course (−41.9%) was maintained during the second one (−43.7%). [ 22 ]
50–250 mg 1x/1–4 weeks Xyosted: Auto-injector: 50–100 mg 1×/week Testosterone cypionate: Depo-Testosterone: Oil solution: 50–250 mg 1x/1–4 weeks Testosterone isobutyrate: Agovirin Depot: Aqueous suspension: 50–100 mg 1x/1–2 weeks Testosterone phenylacetate b: Perandren, Androject: Oil solution: 50–200 mg 1×/3–5 weeks Mixed ...